Literature DB >> 28551473

Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next?

Petra Nijst1, Pieter Martens1, Wilfried Mullens2.   

Abstract

In an important number of heart failure (HF) patients substantial or complete myocardial recovery occurs. In the strictest sense, myocardial recovery is a return to both normal structure and function of the heart. HF patients with myocardial recovery or recovered ejection fraction (EF; HFrecEF) are a distinct population of HF patients with different underlying etiologies, demographics, comorbidities, response to therapies and outcomes compared to HF patients with persistent reduced (HFrEF) or preserved ejection fraction (HFpEF). Improvement of left ventricular EF has been systematically linked to improved quality of life, lower rehospitalization rates and mortality. However, mortality and morbidity in HFrecEF patients remain higher than in the normal population. Also, persistent abnormalities in biomarker and gene expression profiles in these patients lends weight to the hypothesis that pathological processes are ongoing. Currently, there remains a lack of data to guide the management of HFrecEF patients. This review will discuss specific characteristics, pathophysiology, clinical implications and future needs for HFrecEF.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure with recovered ejection fraction; Myocardial recovery; Reverse remodeling

Mesh:

Year:  2017        PMID: 28551473     DOI: 10.1016/j.pcad.2017.05.009

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  8 in total

1.  Pathological changes of the myocardium in reworsening of anthracycline-induced cardiomyopathy after explant of a left ventricular assist device.

Authors:  Hiroaki Hiraiwa; Takahiro Okumura; Shinya Shimizu; Yoshihito Arao; Hideo Oishi; Hiroo Kato; Tasuku Kuwayama; Shogo Yamaguchi; Tomoaki Haga; Tsuyoshi Yokoi; Toru Kondo; Yuki Sugiura; Naoaki Kano; Naoki Watanabe; Kenji Fukaya; Kenji Furusawa; Akinori Sawamura; Ryota Morimoto; Kazuro Fujimoto; Masato Mutsuga; Akihiko Usui; Toyoaki Murohara
Journal:  Nagoya J Med Sci       Date:  2020-02       Impact factor: 1.131

2.  Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.

Authors:  Pieter Martens; Matthias Dupont; Jeroen Dauw; Frauke Somers; Lieven Herbots; Philippe Timmermans; Jan Verwerft; Wilfried Mullens
Journal:  ESC Heart Fail       Date:  2019-09-28

Review 3.  Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology.

Authors:  Ridha I S Alnuwaysir; Martijn F Hoes; Dirk J van Veldhuisen; Peter van der Meer; Niels Grote Beverborg
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.964

4.  Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis.

Authors:  Yibo He; Yihang Ling; Wei Guo; Qiang Li; Sijia Yu; Haozhang Huang; Rongting Zhang; Zhiwen Gong; Jiaxuan Liu; Liyi Mo; Shixin Yi; Disheng Lai; Younan Yao; Jin Liu; Jiyan Chen; Yong Liu; Shiqun Chen
Journal:  Front Cardiovasc Med       Date:  2021-11-25

5.  Meta-analysis of Exercise Training on Left Ventricular Ejection Fraction in Heart Failure with Reduced Ejection Fraction: A 10-year Update.

Authors:  Wesley J Tucker; Rhys I Beaudry; Yuanyuan Liang; Alexander M Clark; Corey R Tomczak; Michael D Nelson; Oyvind Ellingsen; Mark J Haykowsky
Journal:  Prog Cardiovasc Dis       Date:  2018-09-15       Impact factor: 8.194

6.  Long-Term Effects of Angiotensin Receptor-Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction.

Authors:  Gregor Poglajen; Ajda Anžič-Drofenik; Gregor Zemljič; Sabina Frljak; Andraž Cerar; Renata Okrajšek; Miran Šebeštjen; Bojan Vrtovec
Journal:  Diagnostics (Basel)       Date:  2020-07-28

7.  Impact of an extended audit on identifying heart failure patients in general practice: baseline results of the OSCAR-HF pilot study.

Authors:  Miek Smeets; Bert Vaes; Bert Aertgeerts; Willem Raat; Joris Penders; Jan Vercammen; Walter Droogne; Wilfried Mullens; Stefan Janssens
Journal:  ESC Heart Fail       Date:  2020-09-24

8.  Baseline and Dynamic Risk Predictors of Appropriate Implantable Cardioverter Defibrillator Therapy.

Authors:  Katherine C Wu; Shannon Wongvibulsin; Susumu Tao; Hiroshi Ashikaga; Michael Stillabower; Timm M Dickfeld; Joseph E Marine; Robert G Weiss; Gordon F Tomaselli; Scott L Zeger
Journal:  J Am Heart Assoc       Date:  2020-10-07       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.